- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|HMPL309 | xiliertinib (proposed INN)|
|HMPL-309 (theliatinib) is an ATP-competitive EGFR tyrosine kinase inhibitor that was developed for anticancer potential .
Theliatinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but was not submitted to the World Health Organisation for ratification. A genuine application has been made for the INN xiliertinib to represent this molecule (in INN Proposed list 121 of August 2019).
|CAS Registry No.||1353644-70-8 (source: WHO INN record)|
|GtoPdb PubChem SID||363894223|
|Search Google for chemical match using the InChIKey||HJXSISWJKLMCHI-FIFRQSLGSA-N|
|Search Google for chemicals with the same backbone||HJXSISWJKLMCHI|
|Search UniChem for chemical match using the InChIKey||HJXSISWJKLMCHI-FIFRQSLGSA-N|
|Search UniChem for chemicals with the same backbone||HJXSISWJKLMCHI|